What is Lysosomal acid lipase deficiency

Lysosomal acid lipase deficiency (LAL-D) is a rare genetic metabolic disorder where the body lacks the enzyme necessary to break down fats, leading to the dangerous accumulation of lipids in the liver, spleen, and cardiovascular system. This condition can present as either Wolman disease in infancy or the more slowly progressing Cholesteryl Ester Storage Disease (CESD) in children and adults.

What causes Lysosomal acid lipase deficiency?

Lysosomal acid lipase deficiency is caused by mutations in the LIPA gene, which provides instructions for producing the enzyme lysosomal acid lipase (LAL). Without sufficient functional LAL enzyme, the body cannot effectively break down cholesteryl esters and triglycerides within cells. These fats build up in lysosomes—the "recycling centers" of cells—causing damage to vital organs. Because it is an autosomal recessive condition, a child must inherit one faulty copy of the LIPA gene from each parent to develop the disease.

Which body systems are affected by Lysosomal acid lipase deficiency?

The buildup of fats in Lysosomal acid lipase deficiency primarily affects the liver, but it has systemic consequences throughout the body. The most common impacts include:

• Liver: Enlargement (hepatomegaly), inflammation, and the development of fibrosis or cirrhosis.


• Spleen: Enlargement (splenomegaly), which can lead to complications with blood cell counts.


• Cardiovascular System: Dyslipidemia, characterized by high levels of "bad" cholesterol (LDL) and low levels of "good" cholesterol (HDL), which increases the risk of early-onset atherosclerosis.


• Gastrointestinal System: Chronic malabsorption, persistent diarrhea, and failure to thrive in infants.

How is the condition classified?

Clinicians typically categorize Lysosomal acid lipase deficiency into two main clinical presentations, though these exist on a spectrum:

1. Wolman disease: The severe, early-onset form that typically manifests in the first few months of life. It is characterized by rapid liver failure, severe malabsorption, and adrenal calcification.


2. Cholesteryl Ester Storage Disease (CESD): A milder, late-onset form that can be diagnosed in childhood or adulthood. It often progresses more slowly, with patients primarily experiencing liver-related symptoms and cardiovascular issues.

How common is Lysosomal acid lipase deficiency?

Lysosomal acid lipase deficiency is a very rare condition with an estimated prevalence ranging from 1 in 40,000 to 1 in 300,000 individuals, though many experts believe it remains significantly underdiagnosed due to its broad range of symptoms. It affects both males and females equally and has been reported in diverse ethnic populations worldwide. Currently, 5 members of the DiseaseMaps.org community are living with this diagnosis, sharing their unique experiences and navigating the challenges of this rare disorder.

Next steps

• Consult a specialist: Seek guidance from a metabolic specialist, hepatologist, or geneticist who has experience with lysosomal storage disorders.


• Genetic counseling: Speak with a genetic counselor to understand the inheritance pattern and the implications for family members.


• Join a community: Connect with others at DiseaseMaps.org to share experiences and find support from those navigating similar health journeys.


• Stay informed: Monitor clinical trial databases and patient advocacy organizations for the latest therapeutic developments.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Lysosomal acid lipase deficiency


• Orphanet: Lysosomal acid lipase deficiency (ORPHA79385)


• OMIM (Online Mendelian Inheritance in Man): LIPA gene entry (#278000)


• LAL Solace (Patient Advocacy Group)